Whether you are concerned about maintaining your vision or need relief from occasional dry eye symptoms, we share your goal to protect and preserve your eyes.
Omega-3’s (EPA/DHA) essential fatty acids and vitamins are critical for good health. Many of these nutrients are essential; which means that they cannot be made or stored in the body and must be obtained through good nutrition.
PRN Physician Recommended Nutriceuticals®’s omega-3 fish oil are in the most absorbable form: re-esterified triglyceride form (rTG). (Dyerberg J et al, 2010)
Dry Eye Symptoms
Maintaining a healthy surface of the eye and overall tear quality is important for providing ongoing healthy vision. The right formulation of omega-3s can help ensure a healthier tear composition – while providing relief of occasional dry eye symptoms like dryness, redness, or irritation.
PRN’s Dry Eye Omega Benefits® – available in softgel or liquid – is endorsed and used by leading ophthalmologists as a preferred solution for maintaining a healthy ocular surface.
Making sure that you are getting the proper amount of essential nutrients is critical to maintaining healthy vision as you age. Numerous clinical studies have shown that daily supplementation of omega-3s (EPA/DHA) in a purified triglyceride form are necessary for healthy retinal function and overall macular health.
PRN’s evidence-based eye vitamin formula is recommended by top doctors. Based upon the vitamins studied by the National Eye Institute in relation to macular health (Age-related Eye Disease Study AREDS2) along with unique enhancements for further eye health.
PRN’s Macular Health products are formulated based on clinical evidence for maintaining a healthy retina and macula regions of the eye.
Diabetic Retinopathy is a serious health concern.
As many as 74% of people with diabetes could have difficulty digesting dietary fats including Omega-3s. Omega-3 fatty acids, especially DHA has been shown to protect against the progression of Diabetic Retinopathy.
It has been shown in clinical studies that specially formulated Omega-3 fatty acids can help reduce the risk and slow the advancement of diabetic retinopathy.1
Currently, standard of care in late stage treatment modalities for Diabetic Retinopathy are invasive, expensive and limited to laser photo coagulation and/or intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors/steroids. Late stage Diabetic Retinopathy patients can also benefit from EPA/DHA treatment as shown in a two year randomized, single-masked controlled trial. This study followed two groups of subjects with Diabetic Macular Edema (DME).2
Group one received intravitreal ranibizumab alone; group two was given oral DHA/EPA (1,050mg/127mg day) in addition to monthly ranibizumab for four months then followed with as-needed treatments for ranibizumab.
Ranibizumab plus supplementation reduced central subfield macular thickness compared with the injections alone.2 In addition, the supplementation group also had a significant reduction in Omega-6 arachidonic acid levels at 12 months and a significant decrease at 24 months compared with baseline.2 Concomitantly, a similar pattern in the reduction of Omega-6 to Omega-3 ratio was observed.2 The authors state, “the use of intravitreal ranibizumab along with DHA supplementation in patients with DME is extensively applicable to daily clinical practice”.2